De-Risking Vaccine Development Through a Translational Research Public-Private Partnership

Facing the need to de-risk the development of new vaccines, a top-10 biopharma company required help articulating the strategic vision and business case for a translational research public-private partnership.

Shift Health worked with leaders at the company and their partner university to develop a research strategy and associated business plan for a centre that bridges the field-wide gap in translational research, seamlessly integrates expertise and resources between partners and across the company’s network, defines research foci (with an initial focus on improved seasonal and broadly-reactive influenza vaccines), de-risks clinical development of vaccine candidates and provides access to novel vaccine technologies to supplement the company’s pipeline.

The strategy and business plan positioned the client to make evidence-based investment decisions to advance its collaborative research partnership and continue pursuing novel vaccine technologies.